

**(12) UK Patent Application (19) GB (11) 2 310 212 (13) A**

**(43) Date of A Publication 20.08.1997**

**(21) Application No 9603304.8**

**(22) Date of Filing 16.02.1996**

**(71) Applicant(s)**  
**Jose Luis Azumendi**  
**Calle 139 No. 22-15, Santafe de Bogota, Colombia**

**(72) Inventor(s)**  
**Jose Luis Azumendi**

**(74) Agent and/or Address for Service**  
**Raworth Moss & Cook**  
**Raworth House, 36 Sydenham Road, CROYDON,**  
**Surrey, CR0 2EF, United Kingdom**

**(51) INT CL<sup>6</sup>**  
**A61K 39/002 , C07K 14/44**

**(52) UK CL (Edition O )**  
**C3H HFZ H115 H125 H140**  
**A5B BAA B100**  
**C6Y Y402**  
**U1S S1289 S1332 S2419**

**(56) Documents Cited**  
**J.Egypt.Med.Sci. 1969,52(11/12),942-948 Bulletin de**  
**L'Academie Veterinaire de France 1979,53(3),423- 427**  
**Tokai J.Exp.Clin.Med. 1986,11(Suppl.),31-34**  
**Vet.Parasitol. 1991,38,61-65 J.Vet.Med.Sci.**  
**1995,57(6),1049-1051**

**(58) Field of Search**  
**UK CL (Edition O ) A5B BAA BE , C3H HFZ HF4**  
**INT CL<sup>6</sup> A61K 39/002 , C07K 14/44**  
**ONLINE:WPI,CLAIMS,BIOSIS,AGRICOLA,EMBASE,**  
**LSC,MEDLINE,CEABA,DBA,DDF,SCISEARCH,IPA,CHAB**  
**S, NEJM**

**(54) Isolation of the sarcocystine toxin from the genus Sarcocystis**

**(57) A process for the isolation of the toxin, sarcocystine, from a protozoan parasite of the genus Sarcocystis comprises:**

- (i) dialysis of blood serum from a mammal contaminated with the parasite against an aqueous salt solution;**
- (ii) drying the dialysed solution, thereby to isolate the purified toxin.**

**GB 2 310 212 A**

PROCEDURES FOR ISOLATION AND TITRATION OF SARCOCYSTINE  
OR PARASITE TOXIN OF SARCOCYSTIS GENUS

5 This invention relates to a procedural technique for the  
isolation and titration of the toxin sarcocystine which is  
produced by a parasite of the Sarcocystis genus of  
protozoa. This toxin may then be used in the production of  
toxides or vaccines and also in the production of specific  
antibodies against the toxin, as described and claimed in  
10 our co-pending application filed simultaneously herewith  
under reference "SJW/35779.GBA".

More particularly, the present invention relates to a step  
by step procedural technique for isolating the toxin  
15 produced by a parasite of the Sarcocystis genus. In  
particular, material, preferably heart muscle, from an  
Intermediate Host (IH) with Sarcocystis cysts is used to  
contaminate a Final Host (FH). After the development of  
the disease in the Final Host, a percentage of its blood is  
20 extracted and by means of a centrifugation process the  
serum is separated, then dialysed, preferably by passing  
through a sterile Physiological Saline Solution (PSS), and  
it is finally held for storage at a specific temperature.

25 One of the current known methods for isolating the toxin  
includes developing the toxin in macrocysts in sheep  
contaminated with the parasite. According to this method,  
the macrocysts which are formed in the oesophagus of the  
sheep can reach a visible size and contain relatively high  
30 quantities of toxin. Such a method entails the  
inconvenience that the animal must be sacrificed to obtain  
a few millilitres of pure toxin. By contrast the animal is  
kept alive and in good living conditions according to the  
technique of the present invention, so becoming a good

toxin donor from which a substantial volume thereof may be extracted regularly for a long time.

5 In an alternative known method, cell cultures may be utilised as supports for in vitro cultures of Sarcocystis, which allows for a totally-controlled environment to be maintained. The inconvenience arises from the fact that the parasite only begins to produce the toxin 30 or more days after inoculation and then production ends shortly thereafter. Maintenance of these cultures for a long time becomes expensive and they yield a supernatant compound as complex as the animal's blood serum. This latter problem can be overcome using a purification procedure of the present invention.

15 The evidence of the infection with the parasite, known as sarcocystis in man, is usually an accidental finding in the course of histopathological examinations. Protozoa of the Sarcocystis genus behave like an enzoonosis, and it has been reported all over the world that they are a causal agent of many pathologies in man. This parasite mainly affects lower strata people with deficient nutrition although any person may be susceptible to it.

25 Protozoa of the Sarcocystis genus were reported for the first time in 1843 when a researcher by the name of Miescher found tubules in the skelated muscle of a house mouse. Doctors Rommel and Heidorn in 1972 found that the protozoa's life cycle was heterogeneous, with the asexual phase in the prey, the intermediate host, and the sexual phase in the pillager, the final host. At present, 122 species of the protozoa have been identified and in 56 of these two hosts are known. From the zoonosis point of view, those developing the asexual phase in humans are interesting, the final hosts of which are unknown to date,

30

35

and the two which develop the sexual phase in humans which are known.

5       Considering all scientific knowledge at the world level  
concerning multiple sclerosis, lateral and amyotrophic  
sclerosis and the syndrome of chronic fatigue, there is no  
report of any link between a sarcocystis-like protozoa and  
these diseases. According to a review of the literature in  
10       the past months, we have found that multiple sclerosis is  
considered to be closely linked to alterations in the  
immune system, mainly with alterations of the Tcd 4  
lymphocytes.

15       Notwithstanding what has been expressed previously we have  
found that infection due to Sarcocystis gives rise to  
symptoms such as muscle spasms, intermittent diarrhoea and  
chronic fatigue, even to multiple sclerosis. In our  
research, it has been determined that the pathogeny of this  
organism is caused by the toxin from Sarcocystis genus. It  
20       is desirable for this toxin to be isolated so as to be  
inactivated but in such a way that it preserves its  
antigenic capacity, in order to obtain a specific immune-  
induced response from the part of the molecule  
immunologically responsive to a vaccine based on this  
25       toxin.

30       The present invention provides the technique for isolating  
protozoa sarcocystine, i.e., the toxin of the Sarcocystis  
protozoa, which may be later used in the production of  
specific antibodies against the sarcocystine responsible  
for the symptoms of sarcocystosis.

35       In accordance with the present invention there is provided  
a method of isolating a sarcocystine toxin from a mammal  
including the steps of:

(a) dialysing blood serum from a mammal contaminated with the sarcocystine parasite against an aqueous salt solution; and

5 (b) drying the dialysed solution to isolate purified sarcocystine toxin.

It is preferred that a mammal be used as an FH, e.g., a carnivore such as a canine animal. When an FH is used, it is also preferred that the mammal is infected with  
10 Sarcocystis parasite by muscle, and especially cardiac muscle, containing Sarcocystis cysts. It is particularly preferred that the dialysis solution consists of about 9 gm per litre of sodium chloride, although any salt solution of equivalent osmotic pressure can also be used.

15 Preferably a mammal is used as an Intermediate Host, wherein the Intermediate Host is a herbivore, and wherein the Intermediate Host is infected with sporozoites from the stools of the Final Host. Desirably the contaminated  
20 mammal has an absolute lymphocyte count at least 20% higher than its pre-contamination count.

The invention also relates to the determination of the optimum time for bleeding the donor as explained herein  
25 below. This involves the use of the toxicogenic characteristics of sarcocystine. By using the technique of the present invention, it is possible to determine a 98.4% specificity (which means that examination of 100 patients positive to the toxin shows that 98 of them are detected by  
30 the test) and 99.00% sensitivity (which means that, upon examination of 100 patients negative to the toxin, 99 of them are detected by the test), and it may be confirmed through biological titration. The toxin can be titrated in biological tests with a specificity of 99.80% (which means  
35 that upon examining 100 patients positive to the toxin, 100

of them are detected by the test), and a sensitivity of 99.99% (which means that upon examining 100 patients negative to the toxin, 100 of them are detected by the test).

5

The present invention also relates to the desiccation of the toxin isolated by dialysis in order to stabilise it for storage purposes.

10 In a preferred technique, an FH (e.g., a canine animal), of which the absolute number of pre-infection lymphocytes is known, is contaminated with heart muscle of an IH (e.g. a herbivore such as a bovine animal) containing Sarcocystis cysts. It is preferred that the heart muscle does not contain any other aetiological agent. Following  
15 this contamination of the FH, it is expected that such FH will develop sarcocystosis. The absolute lymphocytes count of the FH is an indication of when the next step in the procedure can occur. Once the lymphocyte count reaches a minimum of 20% above the pre-contamination count,  
20 biological titration of the toxin, as described herein below, can be applied to obtain a minimum titre of 3 units. At this point blood may be obtained from the FH. This is likely to occur between 50 and 80 days after contamination. The absolute lymphocyte count of the FH is  
25 an indicator of the toxin concentration due to the mitogenic capacity of sarcocystine. Sarcocystine is highly specific with respect to lymphocytes B, a feature not found in other substances from the blood of a mammal.

30 The FH is bled to obtain the required blood which is collected in a siliconed 500 millilitre sterile Erlenmeyer flask without anticoagulant. The serum is then separated at 800 g for 20 minutes in sterile centrifuge tubes in order to eliminate the corpuscular blood components. The presence of a small degree of haemolysis is acceptable.

35

5 The serum is then dialysed against a sterile PSS composed of about 9 grams of sodium chloride in 1000 cubic centimetres of distilled water for 36 to 48 hours, keeping the temperature between 18 and 25 degrees centigrade and shaking continuously.

10 At this point in the process, the toxin is isolated in the PSS with a minimum purity of 80%. Due to the size of the toxin molecule which is being isolated, temperature and dialysis time, it is possible to eliminate all those molecules which may cause alterations in the toxin usage.

15 The dialysed solution is then dried at a temperature of 37°C in order to remove the water and obtain the toxin concentrate. The dried toxin is then stored in sterile amber flasks and they are kept at room temperature in a dry place.

20 The remaining contaminants located in the desiccated portion of the dialysis are glucose and some minerals, none of which affect the toxicogenic, physical and/or biochemical characteristics of sarcocystine.

25 This procedure results in the isolation of a molecule behaving like hystamine which must be examined in order to determine the toxicogenic titre which is found. It is important to make this titration since epitopes, that is to say, the part of the molecule which is toxicologically active, is the same part of the molecule which is immunologically responsive to both humoral and cellular  
30 defenses. Thus, a strain of the parasite which has proven production of very toxicogenic metabolites must be selected.

To select such a strain, the IH from which the strain is to be obtained must come from an area where the chronic sarcosporidiosis is frequent and with very severe symptoms of the chronic disease demonstrated by between 10,000 and 30,000 bradzooids per gram of wide dorsal muscle. It must also be verified through serological tests that the animal does not suffer from any other disease.

When the muscle which will be used to contaminate the FH is administered, sterile technique should be used. Utilisation of the cardiac muscle is recommended.

With this selected muscle, 4 to 10 FH young adults can be contaminated. These FH must show general vascular lesions and intermittent diarrhoea and that lymphocyte counts must exceed a minimum of 20% above the pre-contamination count.

Once these steps have been carried out and the titration of the toxin (as described below) shows the titre to be greater than or equal to 4 units, the conditions are suitable for the collection and purification of the toxin.

When high toxin volumes are required, the procedure should be applied to larger size mammals (e.g., equine and bovine animals) with slight variations. A stool sample of previously contaminated FH, which has developed the whole picture described above, is taken and the sporozoites contained in the sample are purified. This is done by dissolving the stool sample in over-saturated glucose solution at the proportion of 1 volume of stool per 3 volumes of over-saturated solution, the uppermost part of the preparation is collected, it is diluted in PSS and centrifugated at 300 g for 10 minutes, the supernatant is discarded and the bottom residue is re-suspended in PSS to perform the toxin count.



5 The IH is contaminated with the parasite so prepared at a dosage of 700 sporozoites per kilogram. After 90 days, the IH is found in the chronic phase of the disease with high toxin contents in its blood, which makes it useful for extraction of the toxin. In order to confirm the concentration of the toxin, the same techniques as described above may apply to the FH, i.e., lymphocyte count and/or biological titration of the toxin.

10 Between 40 and 60 days after contamination, the IH may show some symptoms of the severe disease, which may be treated symptomatically but no medicines for killing the Sarcocystis are to be used.

15 Titration Procedure

20 Three groups of 5 to 10 20-gram mice are selected. The toxin is diluted with PSS at two known concentrations, between 0.5 and 1 mg per ml. The first group of mice are orally administered with 0.2 ml of the toxin at dilution 1, the second group of mice are orally administered with 0.2 ml of the toxin at dilution 2, and the third group is used as a control and receives 0.2 ml of PSS without the toxin.

25 Eighteen hours later blood is obtained from all mice to make a total count of lymphocytes. They are then sacrificed to perform a necropsy.

30 In the event that the administration of the toxin has been successful, the mice that received the toxin must present haemoperitoneum among other haemorrhages, while the control animals do not present any haemorrhage at all. Furthermore, the average of the total counts of lymphocytes in the inoculated animals will be higher than the average of the total counts of lymphocytes of the control animals.

35

An estimate of the toxin units ("U") is calculated according to the following formula:

5                      U/mg                      =                      
$$\frac{(\bar{Y} \text{ lri} - \bar{Y} \text{ lrni}) \cdot 50 \cdot d}{\bar{Y} \text{ lrni}}$$

10                      Where:     $\bar{Y} \text{ lri}$                       =                      The average of the total lymphocytes count in the inoculated animals;

15                                       $\bar{Y} \text{ lrni}$                       =                      The average of the total lymphocyte counts in the non-inoculated animals;

                                    d                      =                      Dilution factor in which the toxin was prepared.

20                      A Sarcocystis type toxin unit is the amount of this toxin needed to increase by 10% the average of the total lymphocyte count of the contaminated mice as compared to the non-contaminated mice.

25

30

35

40

CLAIMS:

1. A method of isolating a sarcocystine toxin from a mammal including the steps of:
  - (a) dialysing blood serum from a mammal contaminated with the sarcocystine parasite against an aqueous salt solution; and
  - (b) drying the dialysed solution to isolate purified sarcocystine toxin.
2. A method as claimed in claim 1 wherein the contaminated mammal is a Final Host and is a carnivore.
3. A method as claimed in claim 2 wherein a mammal is used as an Intermediate Host.
4. A method as claimed in claim 3 wherein the Intermediate Host is a herbivore.
5. A method as claimed in claim 3 or claim 4 wherein the Intermediate Host is infected with sporozoites from the stools of the Final Host.
6. A method as claimed in any one of claims 1 to 5 wherein the contaminated mammal is contaminated with muscle containing Sarcocystis cysts.
7. A method as claimed in any one of claims 1 to 6 wherein the contaminated mammal has an absolute lymphocyte count at least 20% higher than its pre-contamination count.
8. A method as claimed in any one of claims 1 to 7 wherein the dialysis solution consists of about 9 grams per litre of sodium chloride.

9. A method as claimed in any one of claims 1 to 8 wherein the dialysis step is carried out for 36 to 48 hours.

5 10. A method as claimed in any one of claims 1 to 9 wherein the dialysis step is carried out at a temperature between 18 and 25 degrees centigrade.

10 11. A method as claimed in claim 1 substantially as hereinbefore described.

12. Sarcocystine toxin when isolated by a method as claimed in any one of the preceding claims.

15

20

25

30

35

[First Hit](#)      [Previous Doc](#)      [Next Doc](#)      [Go to Doc#](#)



Generate Collection

Print

L3: Entry 11 of 13

File: DWPI

Aug 20, 1997

DERWENT-ACC-NO: 1997-388113

DERWENT-WEEK: 199808

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Isolation of a sarcocystine toxin used in the production of e.g. vaccines - comprises dialysis of blood serum from a mammal contaminated with the sarcocystine parasite against an aqueous salt solution and drying the dialysed solution

INVENTOR: AZUMENDI, J L

PATENT-ASSIGNEE: AZUMENDI J L (AZUMI)

PRIORITY-DATA: 1996GB-0003304 (February 16, 1996)

Search Selected

Search ALL

Clear

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> GB 2310212 A	August 20, 1997		013	A61K039/002
<input type="checkbox"/> US 5705607 A	January 6, 1998		004	A61K038/00

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
GB 2310212A	February 16, 1996	1996GB-0003304	
US 5705607A	July 12, 1996	1996US-0695745	

INT-CL (IPC): A61 K 31/12; A61 K 38/00; A61 K 39/002; C07 K 14/00; C07 K 14/44

RELATED-ACC-NO: 1997-415294

ABSTRACTED-PUB-NO: GB 2310212A

BASIC-ABSTRACT:

Isolation of a sarcocystine toxin (I) from a mammal comprises: (a) dialysing blood serum from a mammal contaminated with the sarcocystine parasite against an aqueous salt solution; and (b) drying the dialysed solution to isolate the purified sarcocystine toxin.

USE - (I) is used in the production of toxides or vaccines, and in the production of specific antibodies against the sarcocystine responsible for the symptoms of sarcocystosis.

ADVANTAGE - The animal providing (I) is kept alive, so becoming a toxin donor from which a substantial volume of (I) may be extracted regularly for a long time. The isolation procedure also avoids the maintenance of expensive cultures and a

supernatant compound as complex as the animal's blood serum.

ABSTRACTED-PUB-NO: US 5705607A  
EQUIVALENT-ABSTRACTS:

Isolation of a sarcocystine toxin (I) from a mammal comprises: (a) dialysing blood serum from a mammal contaminated with the sarcocystine parasite against an aqueous salt solution; and (b) drying the dialysed solution to isolate the purified sarcocystine toxin.

USE - (I) is used in the production of toxides or vaccines, and in the production of specific antibodies against the sarcocystine responsible for the symptoms of sarcocystosis.

ADVANTAGE - The animal providing (I) is kept alive, so becoming a toxin donor from which a substantial volume of (I) may be extracted regularly for a long time. The isolation procedure also avoids the maintenance of expensive cultures and a supernatant compound as complex as the animal's blood serum.

CHOSEN-DRAWING: Dwg.0/0 Dwg.0/0

DERWENT-CLASS: B04 C06 D16

CPI-CODES: B04-F06; B04-F06; C04-F06; C04-F06; D05-H07; D05-H13;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)



Application No: GB 9603304.8  
Claims searched: 1 to 12

Examiner: Colin Sherrington  
Date of search: 29 March 1996

**Patents Act 1977**  
**Search Report under Section 17**

**Databases searched:**

UK Patent Office collections, including GB, EP, WO & US patent specifications, in:  
UK Cl (Ed.O): A5B(BAA,BE); C3H(HF4,HFZ)  
Int Cl (Ed.6): A61K 39/002; C07K 14/44  
Other: ONLINE:WPI,CLAIMS,BIOSIS,AGRICOLA,EMBASE,MEDLINE.CEABA,  
DBA,DDF,SCISEARCH,IPA,CHABS,NEJM

**Documents considered to be relevant:**

Category	Identity of document and relevant passage	Relevant to claims
A	J.Egypt.Med.Association 1969,52(11/12),942-948 -I.N.El Akkad et al. "On some pharmaceutical and toxological effects of a protozoan toxin "sarcocystin"	1
A	Bulletin de L'Academie Veterinaire de France 1979,52(3),423-427 - A.Bordjochki et al. "Les proprietes toxiques et immungenes de la sarcocystine et sa sensibilite a des temperatures differentes"	1
A	Tokai J.Exp.Clin.Med. 1986,11(Suppl.),31-34 -H.J.Tietz et al. "Mitogenicity of Extracts from <i>Sarcocystis gigantea</i> on Human and Animal Lymphocytes"	1
A	Veterinary Parasitology 1991,38(1),61-65 -A.Saleque et al. "Toxicity of cyst extract of <i>Sarcocystis fusiformis</i> from buffalo in rabbits and mice"	1
A	J.Vet.Med.Sci. 1995,57(6),1049-1051 -Morihiro Saito et al. "Toxicity and Properties of the Extract from <i>Sarcocystis cruzi</i> cysts"	1

X Document indicating lack of novelty or inventive step	A Document indicating technological background and/or state of the art.
Y Document indicating lack of inventive step if combined with one or more other documents of same category.	P Document published on or after the declared priority date but before the filing date of this invention.
& Member of the same patent family	E Patent document published on or after, but with priority date earlier than, the filing date of this application.